Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Misdiagnosis of narcolepsy caused by a false-positive orexin-A/hypocretin-1 enzyme immune assay.

Literature DB >> 35481446

Misdiagnosis of narcolepsy caused by a false-positive orexin-A/hypocretin-1 enzyme immune assay.

Tomi Sarkanen^1,2, Gabriele Sved³, Maria Juujärvi⁴, Anniina Alakuijala⁵, Markku Partinen^3,6.

Abstract

The diagnosis of narcolepsy is based on clinical history, sleep studies, and, in some cases, cerebrospinal fluid orexin-A/hypocretin-1 measurement. The gold standard for orexin measurement is the radioimmunoassay but other commercial kits are also available, such as the enzyme immune assay (EIA). The specificity of orexin EIA in humans is unknown. We report four cases where orexin levels were measured by EIA and resulted in false positives and the misdiagnosis of narcolepsy. Therefore, orexin EIA measurement should be strongly discouraged in a clinical setting. CITATION: Sarkanen T, Sved G, Juujärvi M, Alakuijala A, Partinen M. Misdiagnosis of narcolepsy caused by a false-positive orexin-A/hypocretin-1 enzyme immune assay. J Clin Sleep Med. 2022;18(8):2075-2078.

Entities: Chemical

Keywords: hypocretin.; narcolepsy; orexin

Mesh：

Substances：

Year: 2022 PMID： 35481446 PMCID： PMC9340599 DOI： 10.5664/jcsm.10014

Source DB: PubMed Journal: J Clin Sleep Med ISSN： 1550-9389 Impact factor: 4.324

12 in total

1. Plasma orexin-A is lower in patients with narcolepsy.

Authors: S Higuchi; A Usui; M Murasaki; S Matsushita; N Nishioka; A Yoshino; T Matsui; H Muraoka; Y Ishizuka; S Kanba; T Sakurai
Journal: Neurosci Lett Date: 2002-01-25 Impact factor: 3.046

2. Considerably Lower Levels of Hypocretin-1 in Cerebrospinal Fluid Is Revealed by a Novel Mass Spectrometry Method Compared with Standard Radioimmunoassay.

Authors: Kjetil Bårdsen; Michaela D Gjerstad; Markku Partinen; Ingeborg Kvivik; Anne Bolette Tjensvoll; Peter Ruoff; Roald Omdal; Cato Brede
Journal: Anal Chem Date: 2019-07-01 Impact factor: 6.986

3. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy.

Authors: M S Aldrich; R D Chervin; B A Malow
Journal: Sleep Date: 1997-08 Impact factor: 5.849

Review 4. Diagnosis of central disorders of hypersomnolence: A reappraisal by European experts.

Authors: Gert Jan Lammers; Claudio L A Bassetti; Leja Dolenc-Groselj; Poul J Jennum; Ulf Kallweit; Ramin Khatami; Michel Lecendreux; Mauro Manconi; Geert Mayer; Markku Partinen; Giuseppe Plazzi; Paul J Reading; Joan Santamaria; Karel Sonka; Yves Dauvilliers
Journal: Sleep Med Rev Date: 2020-03-23 Impact factor: 11.609

Misdiagnosis of narcolepsy caused by a false-positive orexin-A/hypocretin-1 enzyme immune assay.

1. Plasma orexin-A is lower in patients with narcolepsy.

2. Considerably Lower Levels of Hypocretin-1 in Cerebrospinal Fluid Is Revealed by a Novel Mass Spectrometry Method Compared with Standard Radioimmunoassay.

3. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy.

Review 4. Diagnosis of central disorders of hypersomnolence: A reappraisal by European experts.

5. Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients.

6. Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults.

7. Orexin-A measurement in narcolepsy: A stability study and a comparison of LC-MS/MS and immunoassays.

8. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects.

9. From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid.

10. Cerebrospinal Fluid Hypocretin-1 (Orexin-A) Level Fluctuates with Season and Correlates with Day Length.

1. Reduced CSF orexin levels in rats and patients with systemic inflammation: a preliminary study.